Lv7
3320 积分 2021-10-09 加入
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series
3天前
已完结
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
3天前
已完结
Unlocking the Immune System: Advances in Next-generation Immunotherapy for Lung Cancer
13天前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
14天前
已完结
Small Cell Lung Cancer
14天前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
29天前
已完结
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
29天前
已完结
Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review
1个月前
已完结
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
1个月前
已完结
皖公网安备34019202002308
